{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:18:35Z","timestamp":1761895115964},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":7876,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1987,10]]},"abstract":"<jats:p>10 of 20 patients with advanced myeloma treated with a simple regimen consisting of weekly low\u2010dose cyclophosphamide (C; 150\u2013300 mg\/m<jats:sup>2<\/jats:sup>; maximum weekly dose = 500 mg) given intravenously or orally, and alternate\u2010day oral prednisone (P; 50\u2013100 mg) responded clinically and with a fall in serum M protein &gt; 50% or urine M protein &gt; 90%. 3 of these responders were previous primary treatment failures, all having received cyclophosphamide in combination with other drugs given at 3\u2010 to 4\u2010wk intervals. 2 patients treated with this regimen as primary therapy also responded. Although the median survival for the 10 responders was reached at 24.5 months, 3 patients remain alive and well 50+ months from the start of CP therapy. An additional 5 patients had disease stabilization or major improvement in bone pain and\/or pancytopenia for over 12 months despite failure to meet strict criteria for response. The data suggest that disease control may be achieved by the more frequent scheduling of known active drugs such as cyclophosphamide (although it alone or in combination with other drugs may be ineffective when given at standard 3\u2010 to 4\u2010wk intervals) in combination with prednisone on a more continuous basis. This is an effective yet simple therapeutic approach to myeloma with the distinct advantage of less toxicity than the multiple drug regimens in current use. It may have particular applicability to patients who are elderly or debilitated or in patients in whom cytopenia is present initially or develops on standard melphalan\/prednisone regimens.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1987.tb00784.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T03:57:35Z","timestamp":1279425455000},"page":"362-368","source":"Crossref","is-referenced-by-count":22,"title":["Weekly low\u2010dose cyclophosphamide and alternate\u2010day prednisone: An effective low toxicity regimen for advanced myeloma"],"prefix":"10.1111","volume":"39","author":[{"given":"Lorne J.","family":"Brandes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyonel G.","family":"Israels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-00377-5.50018-2"},{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90543-5"},{"key":"e_1_2_1_3_2","first-page":"1971","article-title":"Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine and carmustine (BCNU) (M\u20102 protocol)","volume":"66","author":"Tirelli U.","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_4_2","first-page":"1413","article-title":"Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate\u2010day prednisone","volume":"66","author":"Brandes LJ","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.V55.3.364.364","article-title":"Pretreatment tumor mass, cell kinetics, and prognosis in mutiple myeloma","volume":"55","author":"Durie BGM","year":"1980","journal-title":"Blood"},{"key":"e_1_2_1_6_2","first-page":"17","article-title":"Proposed guidelines for protocol studies. II. Plasma cell myeloma","volume":"1","author":"Chronic Leukemia \u2013 Myeloma Task Force.","year":"1968","journal-title":"Cancer Chemotherapy Rep"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(81)80010-2"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03562.x"},{"key":"e_1_2_1_9_2","first-page":"343","article-title":"Vincristine \u2013 BCNU \u2013 adriamycin\u2010prednisone combination for treatment of melphalan\u2010and\u2010cytoxan\u2010resistant multiple myeloma","volume":"18","author":"Bonnet JD","year":"1977","journal-title":"Proc Am Soc Oncol"},{"key":"e_1_2_1_10_2","first-page":"1265","article-title":"Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone and BCNU","volume":"63","author":"Kyle RA","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood.V54.4.824.824","article-title":"Combination chemotherapy with intermittent 1\u20133 bis (2\u2010chloroethyl)\u20101\u2010nirosourea (BCNU), cyclophosphamide and prednisone for multiple myeloma","volume":"54","author":"Cohen HJ","year":"1979","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197712)40:6<2765::AID-CNCR2820400602>3.0.CO;2-X"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5750.640"},{"issue":"1","key":"e_1_2_1_14_2","first-page":"274","article-title":"The use of intravenous melphalan (L\u2010PAM) in the treatment of multiple myeloma","volume":"52","author":"McIntyre OR","year":"1978","journal-title":"Blood"},{"key":"e_1_2_1_15_2","first-page":"1264","volume-title":"The pharmacological basis of therapeutics","author":"Calabresi P.","year":"1980"},{"key":"e_1_2_1_16_2","first-page":"257","article-title":"A comparison of the effect of prednisone and of a placebo in the treatment of multiple myeloma","volume":"16","author":"Mass RE.","year":"1962","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(73)90116-2"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian R.","year":"1969","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V62.3.572.572","article-title":"Prednisone pulse therapy for refractory myeloma","volume":"62","author":"Alexanian R.","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197910043011402"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V57.2.333.333","article-title":"The growth fraction of human myeloma cells","volume":"57","author":"Drewinko B.","year":"1981","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1987.tb00784.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1987.tb00784.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T17:46:39Z","timestamp":1697910399000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1987.tb00784.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1987,10]]}},"alternative-id":["10.1111\/j.1600-0609.1987.tb00784.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1987.tb00784.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,10]]}}}